🚀 VC round data is live in beta, check it out!
GSK Valuation Multiples
Discover revenue and EBITDA valuation multiples for GSK and similar public comparables like Vertex Pharmaceuticals, Sanofi, Bristol-Myers Squibb, Chugai Pharma and more.
GSK Overview
About GSK
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Founded
1999
HQ
Employees
68.6K
Website
Sectors
Financials (LTM)
EV
$135B
GSK Financials
GSK reported last 12-month revenue of $45B and EBITDA of $15B.
In the same LTM period, GSK generated $33B in gross profit, $15B in EBITDA, and $10B in net income.
Revenue (LTM)
GSK P&L
In the most recent fiscal year, GSK reported revenue of $45B and EBITDA of $15B.
GSK expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $45B | XXX | $45B | XXX | XXX | XXX |
| Gross Profit | $33B | XXX | $31B | XXX | XXX | XXX |
| Gross Margin | 74% | XXX | 70% | XXX | XXX | XXX |
| EBITDA | $15B | XXX | $15B | XXX | XXX | XXX |
| EBITDA Margin | 34% | XXX | 34% | XXX | XXX | XXX |
| EBIT Margin | 30% | XXX | 30% | XXX | XXX | XXX |
| Net Profit | $10B | XXX | $10B | XXX | XXX | XXX |
| Net Margin | 21% | XXX | 21% | XXX | XXX | XXX |
| Net Debt | — | — | $18B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
GSK Stock Performance
GSK has current market cap of $116B, and enterprise value of $135B.
Market Cap Evolution
GSK's stock price is $28.88.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $135B | $116B | 0.1% | XXX | XXX | XXX | $2.37 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialGSK Valuation Multiples
GSK trades at 3.0x EV/Revenue multiple, and 8.8x EV/EBITDA.
EV / Revenue (LTM)
GSK Financial Valuation Multiples
As of March 17, 2026, GSK has market cap of $116B and EV of $135B.
Equity research analysts estimate GSK's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
GSK has a P/E ratio of 12.1x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $116B | XXX | $116B | XXX | XXX | XXX |
| EV (current) | $135B | XXX | $135B | XXX | XXX | XXX |
| EV/Revenue | 3.0x | XXX | 3.0x | XXX | XXX | XXX |
| EV/EBITDA | 8.8x | XXX | 8.9x | XXX | XXX | XXX |
| EV/EBIT | 10.1x | XXX | 10.1x | XXX | XXX | XXX |
| EV/Gross Profit | 4.1x | XXX | 4.3x | XXX | XXX | XXX |
| P/E | 12.1x | XXX | 12.2x | XXX | XXX | XXX |
| EV/FCF | 22.8x | XXX | 21.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified GSK Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
GSK Margins & Growth Rates
GSK's revenue in the last 12 month grew by 2%.
GSK's revenue per employee in the last FY averaged $0.7M.
GSK's rule of 40 is 36% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
GSK's rule of X is 38% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
GSK Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 2% | XXX | 1% | XXX | XXX | XXX |
| EBITDA Margin | 34% | XXX | 34% | XXX | XXX | XXX |
| EBITDA Growth | 3% | XXX | 1% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 36% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 38% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.7M | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 27% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 21% | XXX | 22% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 45% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
GSK Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Vertex Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Sanofi | XXX | XXX | XXX | XXX | XXX | XXX |
| Bristol-Myers Squibb | XXX | XXX | XXX | XXX | XXX | XXX |
| Chugai Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Regeneron | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
GSK M&A Activity
GSK acquired XXX companies to date.
Last acquisition by GSK was on XXXXXXXX, XXXXX. GSK acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by GSK
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialGSK Investment Activity
GSK invested in XXX companies to date.
GSK made its latest investment on XXXXXXXX, XXXXX. GSK invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by GSK
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout GSK
| When was GSK founded? | GSK was founded in 1999. |
| Where is GSK headquartered? | GSK is headquartered in United Kingdom. |
| How many employees does GSK have? | As of today, GSK has over 68K employees. |
| Who is the CEO of GSK? | GSK's CEO is Luke Miels. |
| Is GSK publicly listed? | Yes, GSK is a public company listed on London Stock Exchange. |
| What is the stock symbol of GSK? | GSK trades under GSK ticker. |
| When did GSK go public? | GSK went public in 1972. |
| Who are competitors of GSK? | GSK main competitors are Vertex Pharmaceuticals, Sanofi, Bristol-Myers Squibb, Chugai Pharma. |
| What is the current market cap of GSK? | GSK's current market cap is $116B. |
| What is the current revenue of GSK? | GSK's last 12 months revenue is $45B. |
| What is the current revenue growth of GSK? | GSK revenue growth (NTM/LTM) is 2%. |
| What is the current EV/Revenue multiple of GSK? | Current revenue multiple of GSK is 3.0x. |
| Is GSK profitable? | Yes, GSK is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of GSK? | GSK's last 12 months EBITDA is $15B. |
| What is GSK's EBITDA margin? | GSK's last 12 months EBITDA margin is 34%. |
| What is the current EV/EBITDA multiple of GSK? | Current EBITDA multiple of GSK is 8.8x. |
| What is the current FCF of GSK? | GSK's last 12 months FCF is $6B. |
| What is GSK's FCF margin? | GSK's last 12 months FCF margin is 13%. |
| What is the current EV/FCF multiple of GSK? | Current FCF multiple of GSK is 22.8x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.